Literature DB >> 8892875

Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection.

M J Hosie1, J N Flynn.   

Abstract

Whole inactivated virus (WIV) vaccines derived from the FL4 cell line protect cats against challenge with feline immunodeficiency virus (FIV). To investigate the correlates of protective immunity induced by WIV, we established an immunization regimen which protected a proportion of the vaccinates against challenge. A strong correlation was observed between high virus neutralizing antibody titers and protection following challenge. To investigate further the immune mechanisms responsible for immunity, all of the vaccinates were rechallenged 35 weeks following the initial challenge. Results of virus isolation from peripheral blood mononuclear cells indicated that 9 of 10 vaccinates were protected from viremia following the second challenge, suggesting that vaccine-induced immunity to FIV persisted for at least 8 months. However, more stringent analysis for evidence of infection revealed that 5 of 10 vaccinates harbored virus in lymphoid tissues. Unlike the protection observed immediately following vaccination, which correlated positively with virus neutralizing antibody titer, the ability to resist a second challenge with FIV was more closely correlated with the induction of Env-specific cytotoxic T-cell activity. The results indicate that both virus-specific humoral immunity and cellular immunity play a role in the protection induced in cats by WIV immunization but their relative importance may be dependent on the interval between vaccination and exposure to virus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892875      PMCID: PMC190824     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

2.  A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization.

Authors:  K H Siebelink; G F Rimmelzwaan; M L Bosch; R H Meloen; A D Osterhaus
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

3.  Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers.

Authors:  R Cheynier; P Langlade-Demoyen; M R Marescot; S Blanche; G Blondin; S Wain-Hobson; C Griscelli; E Vilmer; F Plata
Journal:  Eur J Immunol       Date:  1992-09       Impact factor: 5.532

4.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS.

Authors:  J Embretson; M Zupancic; J L Ribas; A Burke; P Racz; K Tenner-Racz; A T Haase
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

5.  Localisation of three epitopes of the env protein of feline immunodeficiency virus.

Authors:  A Avrameas; J G Guillet; L Chouchane; A Moraillon; P Sonigo; A D Strosberg
Journal:  Mol Immunol       Date:  1992-05       Impact factor: 4.407

6.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.

Authors:  G Pantaleo; C Graziosi; J F Demarest; L Butini; M Montroni; C H Fox; J M Orenstein; D P Kotler; A S Fauci
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

7.  Analysis of the amino terminal presequence of the feline immunodeficiency virus glycoprotein: effect of deletions on the intracellular transport of gp95.

Authors:  E B Stephens; E J Butfiloski; E Monck
Journal:  Virology       Date:  1992-10       Impact factor: 3.616

8.  Passive antibody protection of cats against feline immunodeficiency virus infection.

Authors:  T Hohdatsu; R Pu; B A Torres; S Trujillo; M B Gardner; J K Yamamoto
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus.

Authors:  J K Yamamoto; T Hohdatsu; R A Olmsted; R Pu; H Louie; H A Zochlinski; V Acevedo; H M Johnson; G A Soulds; M B Gardner
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

10.  Suppression of virus burden by immunization with feline immunodeficiency virus Env protein.

Authors:  M J Hosie; T H Dunsford; A de Ronde; B J Willett; C A Cannon; J C Neil; O Jarrett
Journal:  Vaccine       Date:  1996-04       Impact factor: 3.641

View more
  22 in total

1.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies.

Authors:  S Giannecchini; D Del Mauro; D Matteucci; M Bendinelli
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus.

Authors:  M J Hosie; T Dunsford; D Klein; B J Willett; C Cannon; R Osborne; J Macdonald; N Spibey; N Mackay; O Jarrett; J C Neil
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

3.  During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein.

Authors:  M Bendinelli; M Pistello; D Del Mauro; G Cammarota; F Maggi; A Leonildi; S Giannecchini; C Bergamini; D Matteucci
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

4.  Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; I Lonetti; L Zaccaro; C Pollera; S Specter; M Bendinelli
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env.

Authors:  Margaret J Hosie; Dieter Klein; James M Binley; Thomas H Dunsford; Oswald Jarrett; James C Neil; Elzbieta Knapp; Simone Giannecchini; Donatella Matteucci; Mauro Bendinelli; James A Hoxie; Brian J Willett
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection.

Authors:  J N Flynn; C A Cannon; J C Neil; O Jarrett
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

7.  Anti-feline immunodeficiency virus (FIV) soluble factor(s) produced from antigen-stimulated feline CD8(+) T lymphocytes suppresses FIV replication.

Authors:  I S Choi; R Hokanson; E W Collisson
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  Adoptive immunotherapy of feline immunodeficiency virus with autologous ex vivo-stimulated lymphoid cells modulates virus and T-cell subsets in blood.

Authors:  J Norman Flynn; Mauro Pistello; Patrizia Isola; Lucia Zaccaro; Barbara Del Santo; Enrica Ricci; Donatella Matteucci; Mauro Bendinelli
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

9.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine.

Authors:  P Mazzetti; S Giannecchini; D Del Mauro; D Matteucci; P Portincasa; A Merico; C Chezzi; M Bendinelli
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

10.  DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies.

Authors:  M J Hosie; J N Flynn; M A Rigby; C Cannon; T Dunsford; N A Mackay; D Argyle; B J Willett; T Miyazawa; D E Onions; O Jarrett; J C Neil
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.